Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
ObjectiveSapropterin dihydrochloride is the first drug for the therapy of phenylketonuria, which is a rare disease that occurs one of 10,000–15,000 newborns. As a result, detailed and comprehensive reports on the safety of sapropterin in large, real-world populations are required. The purpose of thi...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2024-10-01
|
| Colección: | Frontiers in Pharmacology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1486597/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|